Start free
Data and Trust

Every source

The registries, regulators, journals, filings, and feeds Sleuth reads, grouped by what they answer.

See the data page

Sleuth collects every source below at the source and keeps it current. Each one feeds the records in the knowledge base. Use the filter to find a source by name or region.

166 sources

Clinical trials and registries

Who is running what study, where, and at what stage.

SourceRegionWhat it covers
ClinicalTrials.govGlobalTrial registrations, status, arms, endpoints, sponsors, sites and posted results
WHO ICTRPGlobalAggregated records from WHO primary registries worldwide
EU Clinical Trials Register (EudraCT)EUEU trials started before the Clinical Trials Regulation
EU CTISEUEU trial applications, decisions and results under the Clinical Trials Regulation
ISRCTNUKUK primary registry
DRKSEUGerman Clinical Trials Register
ChiCTRChinaChinese Clinical Trial Registry
China Drug Trial Registration Platform (CDE)ChinaMandatory registration for drug trials in China, often earlier and more complete than ChiCTR for industry trials
ITMCTRChinaInternational Traditional Medicine Clinical Trial Registry, via WHO ICTRP
jRCTJapanJapan Registry of Clinical Trials
ANZCTRAPACAustralian New Zealand Clinical Trials Registry
CTRIAPACClinical Trials Registry – India
ReBECLatAmBrazilian Clinical Trials Registry, via WHO ICTRP
CRISKoreaKorea's Clinical Research Information Service, via WHO ICTRP
IRCTMiddle East and AfricaIranian Registry of Clinical Trials, via WHO ICTRP
PACTRMiddle East and AfricaPan African Clinical Trials Registry, via WHO ICTRP
NL-OMONEUOverview of Medical Research in the Netherlands, via WHO ICTRP
RPCECLatAmCuban Public Registry of Clinical Trials, via WHO ICTRP
REPECLatAmPeruvian Clinical Trials Registry, via WHO ICTRP
SLCTRAPACSri Lanka Clinical Trials Registry, via WHO ICTRP
TCTRAPACThai Clinical Trials Registry, via WHO ICTRP

Scientific literature and preprints

What the published science says.

SourceRegionWhat it covers
PubMed / MEDLINEGlobalBiomedical citations and abstracts
PubMed Central Open AccessGlobalFull-text open-access articles
Select peer-reviewed clinical papersGlobalClinical trial publications beyond PubMed's open-access set
Europe PMCEUEuropean full text, with links to grants
bioRxivGlobalBiology preprints
medRxivGlobalClinical and health-science preprints
Chinese-language journals, theses, and conference papersChinaChinese clinical and pharmacology research rarely indexed outside China
CrossrefGlobalDOI metadata across journals, books and proceedings
OpenAlexGlobalOpen index of papers, authors and institutions, used for KOL and lab mapping

Regulatory

What was approved, designated, delayed, or rejected, by which agency.

SourceRegionWhat it covers
FDA drug labels (openFDA / SPL)USPrescribing information, indications, boxed warnings
DailyMedUSCurrent structured product labels from the National Library of Medicine
Drugs@FDAUSApproval history, approval letters and review packages for NDAs and BLAs
FDA approval and decision lettersUSApproval letters and agency communications
FDA Complete Response LettersUSPublished CRLs explaining why applications were not approved
FDA Advisory Committee materialsUSBriefing documents, transcripts, minutes and votes
Orange BookUSApproved small-molecule drugs with patents, exclusivities and therapeutic equivalence
Purple BookUSLicensed biologics, biosimilars, interchangeables and reference product exclusivity
CDER Novel Drug ApprovalsUSAnnual lists of new molecular entities and new biologics
CBER approved biologics and cell & gene therapiesUSVaccines, blood products, cellular and gene therapy approvals
FDA Oncology approval notifications (OCE)USOncology and hematology approvals as they happen
FDA press announcementsUSAgency news releases
Postmarketing Requirements and CommitmentsUSRequired follow-on studies and their status
REMS@FDAUSRisk evaluation and mitigation strategies
FDA guidance documentsUSDraft and final guidance on drug development and review
Product-specific guidancesUSBioequivalence guidance for generics
FDA notices in the Federal RegisterUSApproval withdrawals, advisory committee notices, exclusivity and user fee notices
Orphan Drug Designations and Approvals databaseUSEvery orphan designation with sponsor, date and indication
Breakthrough Therapy designation lists (CDER, CBER)USBreakthrough requests granted and resulting approvals
Accelerated Approval listsUSAccelerated approvals, confirmatory trial status and withdrawals
RMAT designations (CBER)USRegenerative medicine advanced therapy designations
Rare Pediatric Disease designationsUSDesignations eligible for priority review vouchers
Priority review vouchersUSVouchers granted, used and sold (rare pediatric, tropical disease, countermeasure)
EMA CHMP opinions and meeting highlightsEUMonthly positive and negative opinions
EMA European Public Assessment Reports (EPARs)EUFull assessment reports for authorized medicines
EC Union Register of medicinal productsEUEU marketing authorizations and decisions
EU orphan designations (Community Register)EUOrphan designations by sponsor and condition
EMA PRIMEEUMedicines granted priority medicines support
EMA Paediatric Investigation PlansEUPIP decisions and waivers
EMA withdrawn applicationsEUApplications pulled before an opinion
MHRAUKUK approvals and product information
NMPAChinaDrug and biologic approvals and announcements
CDEChinaIND acceptances, priority review, breakthrough therapy and conditional approval lists; review reports
PMDAJapanApprovals list and review reports
MHLW designationsJapanSakigake, orphan and conditional approval designations
Health Canada Drug Product DatabaseCanadaDrugs marketed in Canada
Health Canada Notice of Compliance databaseCanadaCanadian approvals, including conditional NOCs
TGA Australian Register of Therapeutic Goods (ARTG)APACAustralian registrations
TGA Australian Public Assessment Reports (AusPARs)APACPublic assessment reports for Australian approvals
Project OrbisGlobalFDA-led concurrent review of cancer drugs with partner agencies
Access ConsortiumGlobalWork-sharing reviews by the UK, Canada, Australia, Singapore, and Switzerland

Safety and pharmacovigilance

What safety signals exist after approval.

SourceRegionWhat it covers
FAERS (via openFDA)USAdverse event reports for drugs and therapeutic biologics
FDA Drug Safety-related Labeling Changes (SrLC)USLabel safety updates by drug and date
FDA Drug Safety CommunicationsUSAgency safety notices by drug
MedWatch safety alertsUSFDA safety alerts for drugs and biologics
VAERSUSVaccine adverse event reports
EudraVigilance (adrreports.eu)EUSuspected adverse reaction reports in the EU
EMA PRAC signals and meeting highlightsEUSafety signals under EU review
WHO VigiAccessGlobalPublic view of the WHO global safety database

Clinical guidelines and standard of care

How patients are treated today.

SourceRegionWhat it covers
HHS HIV guidelinesUSTreatment guidelines: HIV
ACIP (CDC)USTreatment guidelines: vaccines
Clinical practice guidelines from major medical societiesGlobalTreatment guidelines across therapy areas

Epidemiology and public health

How many patients there are.

SourceRegionWhat it covers
SEERUSUS cancer incidence, prevalence and survival
CDC WONDERUSUS mortality and disease data
NHANES (NCHS)USUS national health and nutrition survey: obesity, diabetes, hypertension, and more
NHIS (NCHS)USUS national health interview survey
Eurostat health databaseEUEU health and causes-of-death data
European Cancer Information System (ECIS)EUEU cancer estimates by country
China CDCChinaChinese disease surveillance and reports
China National Cancer CenterChinaAnnual Chinese cancer statistics
WHO Global Health ObservatoryGlobalGlobal health indicators
OECD Health StatisticsGlobalHealth and disease data for OECD countries
Orphanet prevalence dataGlobalRare disease prevalence and incidence
UN World Population ProspectsGlobalPopulation by age and country

Pricing, reimbursement, and HTA

What a drug costs, and whether it gets paid for.

SourceRegionWhat it covers
CMS ASP pricing filesUSMedicare Part B average sales prices
NADAC (Medicaid)USNational average pharmacy acquisition costs by drug
Medicaid State Drug Utilization DataUSMedicaid prescriptions by drug and state
Medicare Part D Spending DashboardUSMedicare Part D spend and claims by drug
Medicare Part B Spending DashboardUSMedicare Part B spend and claims by drug
Medicare Drug Price NegotiationUSDrugs selected under the Inflation Reduction Act and negotiated prices
NICE technology appraisalsUKEngland reimbursement decisions
G-BA (AMNOG)EUGerman benefit decisions that set pricing
IQWiG (AMNOG)EUGerman benefit assessments behind G-BA decisions
HAS Transparency CommitteeEUFrench benefit ratings
EU Joint Clinical AssessmentsEUEU-wide HTA under the 2025 regulation
China National Reimbursement Drug List (NHSA)ChinaNRDL listings and negotiated prices
Japan NHI price listingsJapanJapanese reimbursement prices

Patents and IP

Who owns what, and when exclusivity ends.

SourceRegionWhat it covers
US Patent and Trademark OfficeUSUS patents and applications
European Patent OfficeEUEuropean patents and applications
Japan Patent OfficeJapanJapanese patents and applications
China National Intellectual Property AdministrationChinaChinese patents and applications
WIPO PCT applicationsGlobalInternational applications, often the first filing on a new program
Orange Book patents and exclusivitiesUSListed patents and exclusivity expiry per drug
Paragraph IV certifications listUSDrugs facing generic patent challenges
Purple Book patent listsUSBiologic patents disclosed in biosimilar litigation

Company filings and disclosures

What companies are required to disclose.

SourceRegionWhat it covers
SEC EDGARUS10-K, 10-Q, 8-K, S-1, F-1, 20-F, 6-K and proxy filings
SEC exhibits (license and collaboration agreements)USFiled deal agreements with economics and terms
SEC ownership filings (13D, 13G, 13F)USActivist stakes and institutional holdings
SEC Form DUSPrivate placements and venture rounds
HKEXnewsChinaHong Kong listings, including 18A biotech prospectuses and announcements
CNInfoChinaShanghai and Shenzhen disclosures, including STAR Market biotechs
EDINETJapanJapanese securities filings
TDnetJapanJapanese timely disclosures
DARTKoreaKorean securities filings

Company websites and investor materials

What companies choose to say.

SourceRegionWhat it covers
Company pipeline pagesGlobalPrograms, targets, modalities and phases as companies list them, public and private
Company press releasesGlobalReleases posted on company newsrooms
Corporate and investor presentationsGlobalPipeline decks and corporate overviews
Earnings call transcriptsGlobalManagement commentary and analyst Q&A
Investor day and R&D day materialsGlobalSlides and transcripts from strategy events
Healthcare investor conference presentationsGlobalFireside chats and presentations at bank-hosted investor conferences and JPM week
Corporate brochures and white papersGlobalCompany-issued technical and platform documents
Posters and publications hosted on company sitesGlobalScientific posters companies post after meetings
Company-hosted KOL eventsGlobalWebcasts with key opinion leaders
Archived versions of company pagesGlobalHistorical versions of pipeline pages, showing what was dropped or changed
Public market dataGlobalShare prices and market caps for listed companies, from public web sources

News and newswires

What happened this week.

SourceRegionWhat it covers
Business WireGlobalCompany press releases
PR NewswireGlobalCompany press releases
GlobeNewswireGlobalCompany press releases
Biotech and pharma trade pressGlobalDaily industry news on approvals, readouts, deals, and financings

Research funding and grants

What academic science is funded before it becomes a company.

SourceRegionWhat it covers
NIH RePORTERUSNIH-funded projects, investigators and linked papers
ARPA-HUSUS advanced health research programs and awards
SBIR / STTR awardsUSUS small business innovation grants to biotechs
EU CORDISEUHorizon Europe and ERC projects

Biology and disease reference data

Public reference sets used alongside Sleuth's own ontology.

SourceRegionWhat it covers
Disease OntologyGlobalDisease classification
MONDOGlobalUnified disease ontology, strong on rare disease
MeSHGlobalNLM's controlled vocabulary used across PubMed
ICD-10-CMUSUS diagnosis codes
ICD-11GlobalWHO international diagnosis codes
NCI ThesaurusUSCancer terminology and drug names
Orphanet nomenclatureGlobalRare disease names, genes and classifications
Open TargetsGlobalTarget–disease evidence
UniProtGlobalProtein sequences and function
HGNCGlobalOfficial gene names
NCBI GeneGlobalGene records
EnsemblGlobalGenome annotation
Human Protein AtlasGlobalTissue and cell expression
ChEMBLGlobalBioactive molecules and assay data
IUPHAR/BPS Guide to PharmacologyGlobalTargets and ligands
PubChemGlobalChemical structures and bioactivity
FDA Global Substance Registration System (UNII)USUnique substance identifiers
RxNormUSNormalized US drug names

Social and alternative signals

Early signals outside formal disclosure.

SourceRegionWhat it covers
WeChat official accountsChinaPipeline, financing and trial updates from Chinese biotechs, translated
Company job postingsGlobalHiring by function and site, an early read on program and commercial build-out
People and executive movesGlobalLeadership changes and team build-outs
Social posts from companies, KOLs, and analystsGlobalReal-time commentary around data releases and meetings
Biotech podcasts and webinarsGlobalExecutive and investor interviews, transcribed

Medical meetings

Abstracts, posters, oral presentation slides, and late-breakers from about 365 medical meetings across 20 therapy areas, with archives back to 2015, including China-focused meetings.

Sell-side research

Research from 35+ banks and brokers. Sell-side research

Don't see a source you need?

Sleuth adds sources when customers need them. Tell us which one